Pycha A, Mian C, Reiter W J, Brössner C, Haitel A, Wiener H, Maier U, Marberger M
Department of Urology, University of Vienna, Austria.
Urology. 1998 Nov;52(5):756-61. doi: 10.1016/s0090-4295(98)00371-9.
Nephrogenic adenoma is a benign metaplastic lesion of the urinary bladder, reported to occur as a response to inflammation, trauma, intravesical therapies, and after renal transplantation. The aim of this study was to evaluate on the basis of chromosomal analysis whether nephrogenic adenoma really is benign.
Twelve renal transplant recipients with histologically verified nephrogenic adenoma were analyzed for numerical aberrations of chromosomes 7, 9, and 17. Results were related to total DNA content, p53 and Ki-67 positivity, and clinical outcome. Ten patients with superficial bladder cancer and 10 healthy renal transplant recipients formed the control groups.
All 12 patients with nephrogenic adenoma had monosomy 9 in a mean of 24.3% (range 20% to 30%) of the evaluated cells; 3 patients had an additional trisomy 7 in a mean of 8% (range 6% to 10%) of the counted cells. Chromosome 1 7 was disomic in all patients. DNA histograms were diploid in 11 of the 12 patients and aneuploid in 1 patient. No p53 and Ki-67 positivity was present in this group. All patients with superficial bladder cancer had monosomy 9 in a mean of 79.8% (range 75% to 85%) of the counted cells. Two patients were found to have an additional trisomy 7 in 50% and 65% of the cells, respectively. The latter had an aneuploid histogram; the others had haploid/diploid histograms. p53 was negative in all specimens. Ki-67 positivity was present in 70% of these patients. All healthy transplant recipients had disomic chromosomal patterns according to diploid DNA histograms and negative immunocytochemical results.
Even if in a lower percentage of cells, aberrations of chromosome 7 and 9 were detected in nephrogenic adenoma. It therefore cannot be excluded that nephrogenic adenomas in immunosuppressed renal transplant recipients may develop into malignant lesions.
肾源性腺瘤是膀胱的一种良性化生病变,据报道其发生与炎症、创伤、膀胱内治疗及肾移植后有关。本研究的目的是基于染色体分析评估肾源性腺瘤是否真的为良性。
对12例经组织学证实为肾源性腺瘤的肾移植受者进行染色体7、9和17数目异常分析。结果与总DNA含量、p53和Ki-67阳性情况以及临床结局相关。10例浅表性膀胱癌患者和10例健康肾移植受者作为对照组。
12例肾源性腺瘤患者中,所有患者评估细胞的平均9号染色体单体缺失率为24.3%(范围20%至30%);3例患者计数细胞的平均7号染色体三体增加率为8%(范围6%至10%)。所有患者的17号染色体均为二体。12例患者中有11例的DNA直方图为二倍体,1例为非整倍体。该组中未发现p53和Ki-67阳性。所有浅表性膀胱癌患者计数细胞的平均9号染色体单体缺失率为79.8%(范围75%至85%)。发现2例患者分别在50%和65%的细胞中有额外的7号染色体三体。后者的直方图为非整倍体;其他患者的直方图为单倍体/二倍体。所有标本的p53均为阴性。这些患者中有70%的Ki-67呈阳性。所有健康移植受者根据二倍体DNA直方图显示染色体模式为二体,免疫细胞化学结果为阴性。
即使在较低比例的细胞中,肾源性腺瘤也检测到了7号和9号染色体异常。因此,不能排除免疫抑制的肾移植受者中的肾源性腺瘤可能发展为恶性病变。